Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
56 results about "Yellow fever" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A viral infection characterized by high fever and jaundice.
Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV in human patients or other animal hosts. The compounds are certain 6-substituted purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV.
Owner:EMORY UNIVERSITY
Purine monophosphate prodrugs for treatment of viral infections
The present invention is directed to compounds, compositions and methods for treating or preventing viral infections using nucleoside analog monophosphate prodrugs. More specifically, HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever in human patients or other animal hosts. The compounds are certain 2,6-diamino 2-C-methyl purine nucleoside monophosphate prodrugs and modified prodrug analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever. This invention teaches how to modify the metabolic pathway of 2,6-diamino 2′-C-methyl purine and deliver nucleotide triphosphate(s) to polymerases at heretofore unobtainable therapeutically-relevant concentrations.
Owner:COCRYSTAL PHARMA INC
Pyrimidine nucleosides and their monophosphate prodrugs for treatment of viral infections and cancer
The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, cytomegalovirus (CMV), herpes viruses (HSV-1, HSV-2), Dengue virus, Yellow fever, or HBV in human patients or other animal hosts. The compounds are certain N4-hydroxycytidine nucleosides derivatives, modified monophosphate and phosphonates prodrugs analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, cytomegalovirus (CMV), herpes viruses (HSV-1, HSV-2), Dengue virus, Yellow fever, and HBV.
Owner:EMORY UNIVERSITY
Antiviral drugs for treatment of arenavrus infection
Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pichinde, and LCMV), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever and Crimean-Congo hemorrhagic fever).
Owner:KINETA FOUR LLC
Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
Owner:EMORY UNIVERSITY
Compositions comprising pathogen-associated molecular patterns and antigens and methods of use thereof
InactiveUS20080063657A1Stimulate immune responseImprove immunitySsRNA viruses positive-sensePeptide/protein ingredientsAntigenYellow fever
Compositions comprise at least a portion of an antigen and at least a portion of a flagellin that lacks a hinge region. Compositions, fusion proteins and polypeptides comprise at least a portion of at least one pathogen-associated molecular pattern and at least a portion of at least one viral protein. The viral protein of the compositions, fusion proteins and polypeptides of the invention are flaviviral proteins, including a West Nile flaviviral protein, a Dengue flaviviral protein, a Langat flaviviral protein, a Kunjin flaviviral protein, a Murray Valley encephalitis flaviviral protein, a Japanese encephalitis flaviviral protein, a Tick-borne encephalitis flaviviral protein, a Yellow fever flaviviral protein and a hepatitis C flaviviral protein. The compositions, fusion proteins and polypeptides are used to stimulate an immune response and protective immunity in a subject.
Owner:VAXINNATE
Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV in human patients or other animal hosts. The compounds are certain 6-substituted purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV.
Owner:EMORY UNIVERSITY
Antiviral activity from medicinal mushrooms
Compounds having unique antiviral properties are prepared from medicinal mushroom mycelium, extracts and derivatives. The compositions are derived from Fomitopsis, Piptoporus, Ganoderma and blends of medicinal mushroom species and are useful in preventing and treating viruses including Orthopox viruses, influenza, avian influenza, Venezuelan Equine Encephalitis, yellow fever, West Nile, Dengue, New World and Old World arenaviruses, hantavirus, Rift Valley fever, sandfly fever, hantavirus, SARS, Rhinovirus and other viruses.
Owner:TURTLE BEAR HLDG LLC
Fluorescence quantitative polymerase chain reaction (PCR) new method for detecting multiple viruses of yellow fever, dengue fever and epidemicencephalitis B and multiple virus detection PCR system
ActiveCN102191338AMicrobiological testing/measurementFluorescence/phosphorescenceFluorescenceYellow fever
The invention discloses a fluorescence quantitative polymerase chain reaction (PCR) new method for detecting multiple viruses of yellow fever, dengue fever and epidemicencephalitis B and multiple virus detection PCR system consisting of primers, probes, a Premix Ex Taq reaction solution and a sterilized Tris buffer. With good singularity and high sensitivity, three pairs of primers and probes are very suitable for simultaneously detecting viruses of yellow fever, dengue fever and epidemicencephalitis B. And there is no cross reaction between the primers and probes and several other entomophily hemorrhagic fever viruses, such as Marburg virus and Rift Valley fever virus.
Owner:CHINESE ACAD OF INSPECTION & QUARANTINE
Purine monophosphate prodrugs for treatment of viral infections
The present invention is directed to compounds, compositions and methods for treating or preventing viral infections using nucleoside analog monophosphate prodrugs. More specifically, HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever in human patients or other animal hosts. The compounds are certain 2,6-diamino 2-C-methyl purine nucleoside monophosphate prodrugs and modified prodrug analogs, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HCV, Norovirus, Saporovirus, Dengue virus, Chikungunya virus and Yellow fever. This invention teaches how to modify the metabolic pathway of 2,6-diamino 2'-C-methyl purine and deliver nucleotide triphosphate(s) to polymerases at heretofore unobtainable therapeutically-relevant concentrations.
Owner:RFS PHARMA +1
Marburg and Ebola dual-virus fluorescent quantitative PCR (Polymerase Chain Reaction) detection method and system
ActiveCN102140533AMicrobiological testing/measurementFluorescence/phosphorescenceEbola virusYellow fever
The invention discloses Marburg and Ebola dual-virus fluorescent quantitative PCR (Polymerase Chain Reaction) detection method and system, wherein the detection system comprises primers, probes, a Premix EX Taq reaction solution and sterilizing Tris water. As two pairs of primers and probes have very good specificity, the detection system has high sensitivity and is suitable for simultaneously detecting Marburg and Ebola viruses without having cross reaction with other kinds of hemorrhagic fever arbovirus, such as yellow fever, dengue and rift valley fever.
Owner:CHINESE ACAD OF INSPECTION & QUARANTINE
Artemisinin with Berberine Compositions and Methods of Making
ActiveUS20130102625A1Effective treatmentBiocideSolid materialProgressive multifocal leukoencephalopathyYellow fever
An all-natural herbal composition and methods of preparing the same are provided. The novel Artemisinin Combination Therapy (ACT) consists of artemisinin and its derivatives and berberine, the two active substances mixed with various selected excipient compounds to form a single pill, tablet or capsule for treatment and prevention of malaria, dengue fever, yellow fever, dysentery, Lyme disease, babesiosis, progressive multifocal leukoencephalopathy, Helicobacter Pylori, and colitis, in adults and children. A tablet or pill for children is formulated to be chewable.
Owner:U S PHYTOTHERAPY
Element fabric health-improving protective clothing capable of killing and repelling mosquitoes
The invention relates to element fabric health-improving protective clothing capable of killing and repelling mosquitoes, which belongs to the technical field of the production of healthy textile multifunctional textile fabric clothing. More than 360 types of mosquitoes are recorded in China. The mosquitoes are fond of sucking blood of warm-blooded animals, infect malaria, filariasis, yellow fever, dengue, epidemic encephalitis B and even H1N1 flu and threaten human health. The element fabric health-improving protective clothing, which is produced by performing nanometered disposal on mixed materials of a plurality of trace elements needed by a human body, a broad-spectrum powerful silver antibacterial agent, an anti-mosquito finishing agent SCJ-951, mosquito-killing pyrethrin and the like and adding the mixture into spinning solution of cotton, flax, fur, polypropylene fiber, polyamide fiber, acrylic fiber and the like, kills and repels mosquitoes and improves health.
Owner:陈欣荣
Process for producing yellow fever attenuated live vaccine by using SPF chicken embryo cells
The invention belongs to the field of biological products, and particularly relates to a process for producing a yellow fever attenuated live vaccine by using SPF chicken embryo cells. According to the process, a 17D attenuated vaccine strain provided by WHO is used, and is subjected to passage adaptation by using chicken embryo cells to prepare virulent seeds, chicken embryo cells cultured by cell factory are inoculated as matrix cells for virus culture, culture is performed, the virus solution is collected, sterilization is performed, a gelatin-free protection agent is added, and freeze drying is performed to prepare the finished product vaccine. According to the present invention, the efficacy index of vaccine meets the WHO standard, other quality test standards meet the requirement ofthe Pharmacopoeia of the People's Republic of China Volume 3 (2015 edition), and the product is used for preventing yellow fever infection.
Owner:无锡鑫连鑫生物医药科技有限公司
Hcv inhibitors
The present invention relates to compounds that are useful in the treatment of viruses belonging to Flaviviridae, including flaviviruses, pestiviruses, and hepaciviruses. The invention includes compounds useful for the treatment or prophylaxis of dengue fever, yellow fever, West Nile virus, and HCV.
Owner:SMITHKLINE BECKMAN CORP
Flavivirus virus like particle
ActiveCN106687590ASsRNA viruses positive-senseViral antigen ingredientsVirus-like particleYellow fever
The present application provides a virus like particle comprising one or more flavivirus structural proteins, and a composition or vaccine comprising thereof, its use in the prevention or treatment of flavivirus infection. The flavivirus structural protein contains at least one amino acid alteration in the envelope region. Examples of flavivirus contains dengue virus.
Owner:VLP THERAPEUTICS LLC
Hcv inhibitors
The present invention relates to compounds that are useful in the treatment of viruses belonging to Flaviviridae, including flaviviruses, pestiviruses, and hepaciviruses. The invention includes compounds useful for the treatment or prophylaxis of dengue fever, yellow fever, West Nile virus, and HCV.
Owner:SMITHKLINE BECKMAN CORP
Cyclocompound of tetrahydropyrrole and dihydroimidazolone as well as preparation and pharmaceutical application thereof
The invention discloses a cyclocompound of tetrahydropyrrole and dihydroimidazolone as well as preparation and pharmaceutical application thereof. The cyclocompound is a compound shown in a formula (I), an isomer or pharmaceutically acceptable salt thereof. The compound, isomer or pharmaceutically acceptable salt thereof can be applied to preparation of medicines used for preventing or treating related diseases (such as dengue fever, dengue hemorrhagic fever, dengue shock syndrome, Zika, Chikungunya, Japanese encephalitis, yellow fever, hepatitis C and West Nile disease) caused by a dengue fever virus and related viruses. (The formula (I) is described in the specification).
Owner:NANJING TECH UNIV
Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
InactiveCN101111514AAvoid infectionEffective immunogenicitySsRNA viruses positive-sensePeptide/protein ingredientsAntigenYellow fever
Compositions comprise at least a portion of an antigen and at least a portion of a flagellin that lacks a hinge region. Compositions, fusion proteins and polypeptides comprise at least a portion of at least one pathogen-associated molecular pattern and at least a portion of at least one viral protein. The viral protein of the compositions, fusion proteins and polypeptides of the invention are flaviviral proteins, including a West Nile flaviviral protein, a Dengue flaviviral protein, a Langat flaviviral protein, a Kunjin flaviviral protein, a Murray Valley encephalitis flaviviral protein, a Japanese encephalitis flaviviral protein, a Tick- borne encephalitis flaviviral protein, a Yellow fever flaviviral protein and a hepatitis C flaviviral protein. The compositions, fusion proteins and polypeptides are used to stimulate an immune response in a subject.
Owner:VAXINNATE
Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses
Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel semicarbazides, sulfonyl carbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to Arenaviridae (Junin, Machupo, Guanavito, Sabia and Lassa), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).
Owner:KINETA FOUR LLC
Antiviral drugs for treatment of arenavirus infection
Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pichinde, and LCMV), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever and Crimean-Congo hemorrhagic fever).
Owner:KINETA FOUR LLC
Use of dipeptide analogue
The invention discloses use of a dipeptide analogue, and particularly relates to use of compounds in formulas (I) and (II), a stereisomer or a pharmaceutically acceptable salt thereof in pharmaceutical aspects. The compounds shown in the formulas (I) and (II) can be utilized as drugs for treating and preventing a disease caused by a dengue fever virus, and simultaneously can become the drugs for treating and preventing the disease caused by other flaviviruses, such as a yellow fever disease, hepatitis c, Japanese encephalitis, forest encephalitis, a disease caused by west nile virus infection, or aids caused by a human immunodeficiency virus (HIV) and the like.
Owner:NANJING TECH UNIV
2'-disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV and influenza infection and cancer in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.
Owner:COCRYSTAL PHARMA INC +1
Hcv inhibitors
The present invention relates to compounds that are useful in the treatment of viruses belonging to Flaviviridae, including flaviviruses, pestiviruses, and hepaciviruses. The invention includes compounds useful for the treatment or prophylaxis of dengue fever, yellow fever, West Nile virus, and HCV.
Owner:SMITHKLINE BECKMAN CORP
Insect repellent and insecticide composition
InactiveCN108477243AEfficient removalRespond effectivelyBiocidePest repellentsAedes aegyptiYellow fever
The invention discloses an insect repellent and insecticide composition. The insect repellent and insecticide composition comprises (a) lemon grass oil (citronella oil), (b) p-menthyl-3, 8-diol, (c) vanillin and (d) a transport medium, wherein the mass ratio of p-menthyl-3, 8-diol to lemon grass oil (citronella oil) is 10 to 2:1. The insect repellent and insecticide composition reduces the limitation of the existing product based on the known natural ingredients. Through the synergism of two or more insect repellent materials, the unique formula can produce additional benefits and superior effects. The research results show that the novel composition can effectively repel mosquitoes and has a strong repellent effect. The formula containing lemongrass oil (citronella oil) and p-menthyl-3, 8-diol can effectively resist mosquito-borne malarial mosquito and Aedes aegypti transmitting dengue fever and yellow fever.
Owner:黄珊珊
Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV, HEV, and influenza infection and cancer in human subjects or other animal hosts.
Owner:EMORY UNIVERSITY
Cyclic formyl and cyclic ketone compounds as well as preparation method and pharmaceutical application thereof
ActiveCN111518102APromote infectionFunction increaseAntibacterial agentsGroup 4/14 element organic compoundsEscherichia coliInfection induced
The invention discloses cyclic formyl and cyclic ketone compounds as well as a preparation method and a pharmaceutical application thereof. The compound shown in (I) has a good function of inhibitinginfection and replication of Zika viruses and dengue viruses; the compounds can be used as medicines for treating and preventing diseases caused by Zika virus and dengue virus. The compound can be used as a medicine for treating and preventing diseases caused by other flaviviruses, such as yellow fever, west nile virus infection, encephalitis B caused by encephalitis B virus infection, chikungunyavirus infection, hepatitis C, forest encephalitis, AIDS caused by HIV, diseases caused by hand-foot-and-mouth virus infection and the like. The compound can be used for treating diseases caused by bacterial infection, including ulcerative colitis and Crohn's disease of inflammatory bowel disease, diseases caused by escherichia coli, diseases caused by staphylococcus aureus and the like, and diseases caused by acinetobacter baumannii.
Owner:NANJING TECH UNIV
Lentivirus vaccine based on the recombinant viral vaccine against yellow fever
The present invention relates to an attenuated, recombinant viral vaccine against yellow fever which expresses heterologous sequences of a lentivirus and is used as an immunisation agent to induce an immune response to lentivirus.
Owner:FUNDACAO OSWALDO CRUZ FIOCRUZ +1
Yellow fever antigen near infrared fluorescence detection kit and application thereof
InactiveCN108226507ADetection specificityStrong specificityImmunoassaysAgainst vector-borne diseasesReagent stripCellulose
The invention relates to the technical field of biologics and in particular relates to a yellow fever antigen near infrared fluorescence detection kit and application thereof. The invention provides the yellow fever antigen near infrared fluorescence detection kit which comprises a reagent strip, wherein the reagent strip is positioned on a back plate; the reagent strip comprises a sample pad, a glass cellulose membrane marked by using an immunofluorescence probe, a nitrocellulose membrane coated by an LP antibody, and water absorption paper in sequence from a sample feeding end. By adopting the detection kit provided by the invention, urea or sputum of a patient can be adopted as a detection sample, and with the reference to the detection kit and a near-infrared fluorescence detection technique, specific and dissoluble LP antigen in a patient specimen can be rapidly and accurately detected.
Owner:JIANGSU WISE SCI & TECH DEV
Yellow fever antigen near-infrared fluorescence detection kit
InactiveCN108458996ADetection specificityStrong specificityBiological material analysisFluorescence/phosphorescenceCelluloseReagent strip
The invention relates to the field of biotechnology, particularly to a yellow fever antigen near-infrared fluorescence detection kit and uses thereof, and provides a yellow fever antigen near-infraredfluorescence detection kit, which comprises a reagent strip positioned on a back plate, wherein the reagent strip sequentially comprises a sample pad, a glass cellulose membrane labeled with an immunofluorescent probe, a nitrocellulose membrane coated with a LP antibody, and water absorption paper from a sample adding end. According to the present invention, the detection kit can rapidly and accurately detect the specific and soluble LP antigen in the patient specimen by using the urine or sputum of the patient as the detection sample and combining with the near-infrared fluorescence detection technology.
Owner:ZHENJIANG XIANCHUANG BIOTECH CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com